FRI0290 Co-Morbidities in Osteoporotic Patients: A Retrospective Study
Authors: A.M. Ata, F.Y.G. Kutsal
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In patients with osteoporosis a wide range of co-morbidities often adversely affect the treatment of osteoporosis. Physicians and patients primarily focus on systemic co-morbidities and they can easily be able to neglect or underestimate the diagnosis and treatment of osteoporosis which is initially characterized as a clinically silent disease. <h3>Objectives</h3> The aim of this study is to investigate the presence of co-morbidities in inpatients who were diagnosed with osteoporosis in Hacettepe University Faculty of Medicine, Department of Physical Medicine and Rehabilitation. <h3>Methods</h3> After the approval of Hacettepe University Clinical Ethics Committee, medical records of 2445 cases hospitalized in Department of Physical Medicine and Rehabilitation were retrospectively analyzed between the years of 2003-2013. Bone mineral density measurement with Dual Energy X-Ray Densitometry were performed in 502 patients. Of these, 190 patients between the ages of 16-94 were diagnosed with osteoporosis, as defined by the World Health Organization T-score ≤-2.5 and they were studied to record their age, gender, body mass index and presence of co-morbid diseases. <h3>Results</h3> Mean age of the patients was 69.38±13.53 years (range 16-94) while mean results for height, weight and body mass index were 158.47±9.27 cm (129-205), 69.09±13.46 kg (42-120) and 27.60±5.45 (17.3-50.6) respectively. There were 53 patients under 65 years (mean age: 51.1) and 137 patients 65 years and over (mean age 76.0). Of these patients, 152 were females (80%) and 32 were males (20%). It was found that 30.6% of the osteoporotic patients who were over 65 and 13.2% of the ones under 65 had four or more co-morbid diseases. The most common co-morbidity was found to be hypertension (64.2%). It was followed by hyperlipidemia (27.3%), diabetes mellitus (19.4%), hypothyroidism and thyroidectomy (16.3%), coronary artery disease (14.7%), chronic obstructive pulmonary disease (14.2%), cerebrovascular accident (12.6%), total abdominal hysterectomy and bilateral salpingo-oophorectomy (10.5%), total knee and hip arthroplasty (9.4%), multiple sclerosis (7.3%), Parkinson9s disease (4.2%), breast cancer (3.6%), benign prostate hypertrophy (3.6%), congestive heart failure (3.1%), fractures (2.6%), dementia (1.5%), hyperparathyroidism (1.5%) and migraine (1.0%), depression (1.0%), prostate cancer (1.0%), lymphoma (1.0%), gastritis (1.0%), chronic renal disease (1.0%) and nephrectomy (1.0%). <h3>Conclusions</h3> Patients with one or more co-morbidities should be followed strictly in terms of primary or secondary osteoporosis and detailed risk calculation should be done. Not only the preventive measures, but early diagnosis and effective treatment should be taken account seriously as well. Treatment recommendations for the patients with several co-morbidities must take patient compliance into account. <h3>References</h3> O9Malley CD1, Tran N, Zapalowski C, Daizadeh N, Olenginski TP, Cauley JA; Multimorbidity in women with and without osteoporosis: results from a large US retrospective cohort study 2004-2009. Osteoporos Int. 2014; 25(8):2117-30. Pasoto SG, Yoshihara LA, Maeda LC, Bernik MM, Lotufo PA, Bonfa E, Pereira RM. Osteoporotic hip fractures in non-elderly patients: relevance of associated co-morbidities. Rheumatol Int. 2012; 32(10):3149-53. <h3>Disclosure of Interest</h3> None declared